TSRC2011(65) - Document not peer-reviewed

Utility of Biomarkers in Assessing Exposure to Cigarette Smoke Constituents in Adult Smokers

Mohamadi Sarkar, M.Pharm., Ph.D., FCCP

Altria Client Services Inc.



Outline

- Introduction
- Categorization of Biomarkers of Exposure
 - Tobacco Specific
 - Non-tobacco Specific
- Factors Influencing Biomarker of Exposure
- Characterization of Some Biomarkers of Exposure
- Alternative Methods of Estimating Exposure
- Conclusions



FSRC2011(65) - Document not peer-reviewed

Introduction



- There are thousands of constituents in cigarette smoke, which makes assessment of total systemic exposure to cigarette smoke challenging.
- The role of specific constituents in causing smoking related disease is still not well established



Exposure is the First Step towards Potential Biological Outcome from Smoking



Adapted from: National Research Council. 1987. Biological markers in environmental health research. Environmental Health Perspectives 74:1-191.



Outline

- Introduction
- Biomarkers of Exposure
- Categorization of Biomarkers of Exposure
 - Tobacco Specific
 - Non-tobacco Specific
- Factors Influencing Biomarker of Exposure
- Characterization of Some Biomarkers of Exposure
- Alternative Methods of Estimating Exposure
- Conclusions



Biomarkers of Exposure



A tobacco constituent or metabolite that is measured in a biological fluid or tissue that has the potential to interact with a biological macromolecule; sometimes considered a measure of internal dose

*Clearing the smoke: Assessing the science base for tobacco harm reduction. Stratton K, Shetty P, Wallace R and Bondurant S. Eds. (2001) Institute of Medicine Publication, National Academy Press Washington DC



2011_TSRC03_Sarkar.pdf

Cigarette Smoke is a Complex Mixture



7 | Altria Client Services | Mohamadi Sarkar - 65th TSRC Presentation | 9.19.111

Altria Client Services

Biomarkers of Exposure

	Biomarker of Exposure	Smoke Constituent	Sample Matrix
Г	Carboxyhemoglobin	Carbon monoxide	Blood
	3-hydroxypropylmercapturic acid (3-HPMA)	Acrolein	Urine
	Monohydroxybutenylmercapturic acid (MHBMA) and dihydroxybutylmercapturic acid (DHBMA)	1,3-Butadiene	Urine
Vapor Phase	S-phenylmercapturic acid	Benzene	Urine
	3-hydroxy-1-methylpropylmercapturic acid 2-carboxy1-1-methylethylmercapturic acid	Crotonaldehyde	Urine
	4-Aminobiphenyl adducts, 4-Aminobiphenyl	Aminobiphenyl	Blood / Urine
	o-toluidine, 2-aminonaphthalene	Aromatic amines	Urine
Particulate Phase	Nicotine, cotinine, <i>trans</i> -3'-hydroxycotinine and their glucuronide conjugates ^A	Nicotine (T)	Urine
	Nicotine, Cotinine, <i>trans</i> -3'-hydroxycotinine	Nicotine (T)	Plasma
	Total NNAL ^B	NNK ^C (T)	Urine
	Total NNN ^D	NNN (T)	Urine
	Total 1-hydroxypyrene	Pyrene	Urine
L	3-hydroxy-benzo[a]pyrene	Benzo[a]pyrene	Urine

(T) Tobacco specific

^AThe molar sum of nicotine and its five major metabolites were expressed as nicotine equivalents (NE) ^B 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone ; ^DN'-nitrosonornicotine



Philip Morris USA Study Total Exposure Study -TES

 The TES was a stratified, multi-center, cross-sectional study that had 3585 evaluable adult smokers and 1077 evaluable non-smokers from 31 states (39 investigative sites) across the U.S.





Clinical Models to Assess Exposure

Switching Studies

- Short Term
 - Randomized
 - Parallel Group
 - Confined to the Clinic
 - Appropriate Comparators
 - Daily Investigations
 - Biomarkers of exposure
 - 24 hour urine and precisely timed blood measurements
 - Behavioral Measurements



Primary Objective of Short Term Studies – Exposure Assessment



Clinical Models to Assess Exposure

Adult

Smokers

Baseline

neasures

while

smoking own

cigarette

Day -1

A N

D

Ο

Ο

N

Day 1

Short Term Study

Continue smoking Own

Cigarette

Switch to

Test Product

Stop

Smoking

Day 8

Month 1

Month 2

Switching Studies

- Long Term
 - Randomized
 - Parallel Group
 - Ambulatory
 - Ad Libitum Product use
 - Appropriate Comparators
 - Monthly Investigations
 - Biomarkers of exposure
 - Biomarkers of potential harm
 - 24 hour urine and blood measurements
 - Behavioral Measurements

Primary Objective of Long Term Studies – To assess biomarkers of exposure and potential harm under ambulatory product use behavior

Month 4

Long Term Study

Continue smoking Own Cigarette

Continue Using Test Product

Month 3



Month 5

Categorization of Biomarkers of Exposure Tobacco Specific Biomarkers

Biomarker		Adult Smoker (AS)	Non-Smoker (NS)	Ratio <u>AS</u>
Nicotine Equivalents (mg/24h)	Mean ± SD	13.1 ± 7.89	0.120 ± 1.22 ~78% BLLOQ	109.2
Serum Cotinine (ng/mL)	Mean ± SD	184 ± 106	4.05 ± 21.3 ~98% BLLOQ	45.4
Total NNAL (ng/24h)	Mean ± SD	433 ± 306	10.8 ± 68.5 ~88% BLLOQ	40.1
NNN (ng/24h)	Mean ± SD	24.1 ± 29.41	1.0 ± 6.91 ~94% BLLOQ	24.1

Data from the Total Exposure Study; N=3585 AS; N1077 NS for all biomarkers except NNN (n=371 for AS and N=179 for NS); BLLOQ=Below Lower Limit of Quantification; Roethig *et al* Nicotine Tob Res. 2009 Oct;11(10):1216-25.

Biomarkers of Exposure to tobacco specific constituents provide clear discrimination between AS and NS; however, secondhand exposure or misclassification should be considered



Categorization of Biomarkers of Exposure Non-Tobacco Specific Biomarkers

Biomarker		Adult Smoker (AS)	Non-Smoker (NS)	Ratio <u>AS</u> NS
S-PMA (µg/24h)	Mean ± SD	6.5 ± 4.93	0.6 ± 0.47	11.03
Urine mutagenicity (revertants/24h)	Median	26549	3283	7.42
4-ABP (ng/24h)	Mean ± SD	20.5 ± 11.05	3.1 ± 1.84	6.59
3-OH B(a)P (pg/24h)	Mean ± SD	218.7 ± 307.09	104.2 ± 163.28	2.10
o-toluidine (ng/24h)	Mean ± SD	414.1 ± 221.17	346.8 ± 1083.5	1.19

N=200 for each group from the Total Exposure Study; some biomarkers had slightly different sample sizes Sarkar M *et al* manuscript under review , Cancer Epidemiology Biomarkers and Prevention.

Although statistically significantly different between NS & AS, other sources of exposure may confound the interpretation from such "non-tobacco specific biomarkers" TSRC2011(65) - Document not peer-reviewed

Outline

- Introduction
- Categorization of Biomarkers of Exposure
 - Tobacco Specific
 - Non-tobacco Specific
- Factors Influencing Biomarker of Exposure
- Characterization of Some Biomarkers of Exposure
- Alternative Methods of Estimating Exposure
- Conclusions



Factors influencing Biomarkers of Exposure – Half-Life



3-HPMA=3-hydroxypropyl mercapturic acid

Total NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronide conjugates

Data, shown as Median values, adapted from Sarkar MA et al Nicotine Tob Res. 2008 Dec;10(12):1761-72.



TSRC2011(65) - Document not peer-reviewed

Factors influencing Biomarkers of Exposure – Specificity



Data, shown as Mean + SD values, adapted from Sarkar MA et al Nicotine Tob Res. 2008 Dec;10(12):1761-72.



Factors influencing Biomarkers of Exposure – Variability



Data, shown for individual subjects; NE=Nicotine Equivalents; Liang et al Manuscript under review



Factors influencing Biomarkers of Exposure – Study Conduct Setting









Factors influencing Biomarkers of Exposure – Study Conduct Setting





Long-term (Ad libitum)



Difficult to ascertain protocol adherence

Nicotine Equivalents = Nicotine and five of its metabolites expressed as molar equivalents of nicotine measured in 24 hour urine

Data, shown as Mean <u>+</u> SD values, adapted from Sarkar MA *et al* Nicotine Tob Res. 2008 Dec;10(12):1761-72. and Roethig *et al* Nicotine Tob. Res. 2009 Oct;11(10):1216-25.



Outline

- Introduction
- Categorization of Biomarkers of Exposure
 - Tobacco Specific
 - Non-tobacco Specific
- Factors Influencing Biomarker of Exposure
- Characterization of Some Biomarkers of Exposure
- Alternative Methods of Estimating Exposure
- Conclusions



Characterization of Nicotine Exposure¹

Pearson Correlation Coefficient (r) values for the relationship between Nicotine Equivalents and biomarkers of exposure

	Particulate Phase			Particulate Phase Gas-Vapor Phase			
Cigarette Type ²	Total NNAL	Total 1-OHP	Plasma Cotinine ³	3-HPMA	S-PMA	МНВМА	COHb ³
CC6	0.67	0.52	0.75	0.84	0.65	0.62	0.76
CC11	0.50	0.51	0.67	0.80	0.56	0.47	0.62
CC15	0.72	0.54	0.43	0.69	0.61		0.53

²Different cigarette types reflect different products with varying machine measured tar yields,

CC6= 6 mg tar; CC11=11 mg tar and CC15 = 15 mg tar as measured by the Cambridge Filter Method.

³ Collected at 19:00 daily.

p < .0001 for all the correlation significance testing. ¹Wang J, Liang Q, Mendes P, Sarkar M. Biomarkers. **16**:144-54, 2011

24H urinary Nicotine Equivalents is a good surrogate of overall smoke exposure



2011_TSRC03_Sarkar.pdf

Characterization of urinary excretion of NNN*

Biomarker	Independent variable	p-value	r
NNN	Num of cig	<.0001	0.21
	NE	<.0001	0.27
	Total NNAL	<.0001	0.29

24H urinary excretion of NNN does not appear to be a representative biomarker of the particulate phase from cigarette smoke

Sarkar M et al manuscript under review , Cancer Epidemiology Biomarkers and Prevention



Characteristics of Biomarkers of Exposure to Polycyclic Aromatic Hydrocarbons

Biomarker	Independent variable	p-value	r
3-OH BaP	Num of cig	0.7559	0.02
	NE	0.0001	0.19
	1-hydroxy pyrene	<0.0001	0.79

24H urinary excretion of 3-hydroxy benzo(a)pyrene does not appear to be a representative biomarker of exposure

Sarkar M et al manuscript under review, Cancer Epidemiology Biomarkers and Prevention



Characterization of Nicotine Exposure¹

Pearson Correlation Coefficient (r) values for the relationship between Nicotine Equivalents and biomarkers of exposure

	Particulate Phase			Particulate Phase Gas-Vapor Phase			
Cigarette Type ²	Total NNAL	Total 1-OHP	Plasma Cotinine ³	3-HPMA	S-PMA	МНВМА	COHb ³
CC6	0.67	0.52	0.75	0.84	0.65	0.62	0.76
CC11	0.50	0.51	0.67	0.80	0.56	0.47	0.62
CC15	0.72	0.54	0.43	0.69	0.61		0.53

²Different cigarette types reflect different products with varying machine measured tar yields,

CC6= 6 mg tar; CC11=11 mg tar and CC15 = 15 mg tar as measured by the Cambridge Filter Method.

³ Collected at 19:00 daily.

p < .0001 for all the correlation significance testing. ¹Wang J, Liang Q, Mendes P, Sarkar M. Biomarkers. **16**:144-54, 2011

24H urinary Nicotine Equivalents is a good surrogate of overall smoke exposure



Characteristics of Biomarkers of Exposure to 4-aminobiphenyl

Independent	p-value	r
variable		
Num of cig	<.0001	0.44
NE	<.0001	0.64
4-ABP Hb Adducts	<.0001	0.31
	Independent variable Num of cig NE 4-ABP Hb Adducts	Independentp-valuevariableNum of cig<.0001

24H urinary excretion of 4-aminobiphenyl and its hemoglobin adducts serve unique purposes in assessing cigarette smoke exposure

Sarkar M et al manuscript under review, Cancer Epidemiology Biomarkers and Prevention



TSRC2011(65) - Document not peer-reviewed

Characteristics of Biomarkers of Exposure to **Aromatic Amines**

Biomarker	Independent variable	p-value	r
2-aminonaphthalene	Num of cig	<.0001	0.55
	NE	<.0001	0.73
o-toluidine	Num of cig	0.0006	0.24
	NE	<.0001	0.30

24H urinary excretion of o-toluidine does not appear to be a representative biomarker of aromatic amines from cigarette smoke

Sarkar M et al manuscript under review, Cancer Epidemiology Biomarkers and Prevention



Relationship of Urine Mutagenicity with Biomarkers of Exposure

Parameter	T Value	P Value	Partial R-square
Intercept	-1.63	0.1056	
2-Aminonaphthalene (ng/24h)	10.67	<.0001	0.5631
o-Toluidine (ng/24h)	2.22	0.0285	0.0116

The association of 2-aminonaphthalene with urine mutagenicity suggests that this biomarker of exposure may have some biological relevance

Sarkar M et al manuscript under review, Cancer Epidemiology Biomarkers and Prevention



TSRC2011(65) - Document not peer-reviewed

Outline

- Introduction
- Categorization of Biomarkers of Exposure
 - Tobacco Specific
 - Non-tobacco Specific
- Factors Influencing Biomarker of Exposure
- Characterization of Some Biomarkers of Exposure
- Alternative Methods of Estimating Exposure
- Conclusions



Alternative Methods to Estimate Exposure: Mouth Level Exposure (MLE)

- MLE is an unobtrusive technique based on measurements made on cigarettes actually smoked in an ambulatory environment.
- The retained smoke particulates and nicotine in the mouth-end filter section of a smoked cigarette are measured.
- However this method does not appear to represent actual exposure.

Percent change in mean daily exposure: mouth level exposure (MLE) compared to biomarker of exposure (BOE)

	MLE	BOE
Nicotine	-15.7	-34.1 (NE)
NNK	-34.1	-21.3 (NNAL)
Acrolein	-2.7	-22.9 (3-HPMA)

Data adapted from Shepperd *et al* Regul. Toxicol. Pharmacol. 2011, shown as % reduction in constituent or biomarker when switching to a test product



Conclusions

- Several factors, in addition to smoking behavior, influence biomarkers of exposure
- Some of the biomarkers have poor discriminatory power (e.g. o-toluidine) and would not be suitable for estimating exposure in adult smokers.
- Nicotine equivalents should be considered as a surrogate biomarker of total cigarette smoke exposure.

